Benefits Investigation: What a Complete BI Covers

Illustration of a benefits investigation checklist covering benefit type, prior auth, site of care and cost share

"We already ran eligibility. Why does this therapy need a benefits investigation?" The infusion coordinator has a point. The 271 came back active, the plan is commercial PPO, and the deductible is listed. What the response does not say is whether this infused drug sits under the medical or pharmacy benefit, whether the plan will let the practice buy and bill it, whether the hospital outpatient department is an approved site of care, or whether a preferred product has to come first.

A benefits investigation (BI) answers those questions. Eligibility confirms that a patient has coverage. A BI confirms whether and how a specific drug or service is covered for this patient, at this site of care, under which benefit, with which authorization and sourcing rules, and at what cost share. For specialty therapies, it is the record that pharmacy, authorization and billing teams work from before anyone orders a dose.

TL;DR

  • Eligibility is not a BI. A 271 confirms coverage, dates and cost-sharing amounts; a BI answers whether a specific drug is covered for this patient, under which benefit, at which site and through which sourcing route.
  • A complete BI is field by field. Benefit type, prior authorization and where to submit, step therapy or formulary status, site of care, specialty pharmacy or buy-and-bill, cost share with amounts met, the codes the answer applies to, and a reference number.
  • BIs go stale. Plan years reset, eligibility changes and payer drug policies update, so verify before the first dose and again when the plan or policy changes.
  • Four service models do this work. Manufacturer hubs, specialty pharmacies, in-house staff and automated or AI agent workflows each draw on a different mix of payer sources.
  • SuperDial automates payer and PBM follow-up for pharma patient access. It retrieves from clearinghouses, portals, APIs and EDI where those sources are available, continues by phone when more is needed, and returns structured fields.

How a benefits investigation differs from an eligibility check

X12 describes the 271 eligibility response as carrying information that "includes but is not limited to: benefit status, explanation of benefits, coverages, dependent coverage level, effective dates, amounts for co-insurance, co-pays, deductibles, exclusions and limitations" (X12 transaction sets). That is plan-level information about the member, not how one high-cost drug will be handled at one location. Our guide to why insurance eligibility checks still fail covers the general gaps in a bare coverage response.

Specialty drugs add a second layer, because the transaction depends on the benefit. Under the HIPAA standards at 45 CFR 162.1202, retail pharmacy eligibility runs on the NCPDP Telecommunication Standard (moving to version F6, with a dual-use period from August 14, 2027 through April 14, 2028), while professional and institutional eligibility runs on the X12 270/271. A medical-side 271 and a pharmacy-side response come from different systems, and a BI has to reconcile them.

Which benefit is responsible comes first, and our post on medical vs. pharmacy benefit for specialty drugs covers that split in depth. In short, the pharmacy benefit typically covers self-administered drugs dispensed under a prescription, the medical benefit typically covers drugs given by a professional, and a specialty drug can fall under either or both depending on the plan. For Medicare, CMS's Benefit Policy Manual says Part B covers drugs furnished "incident to" a physician's service "provided that the drugs are not usually self-administered by the patients who take them," and each Medicare Administrative Contractor "must make its own individual determination on each drug."

What a complete benefits investigation includes

A useful BI answers one question per field: what will this plan require, and what will it pay, for this drug, this patient and this site? Many answers come from payer drug policies rather than the eligibility response.

FieldWhy it mattersWhere it usually comes from
Active coverage, plan type and effective datesConfirms coverage on the planned date of service and which plan rules apply271 or NCPDP eligibility response; payer portal
Responsible benefit (medical or pharmacy)Decides the authorization channel, claim format and who bills for the drugPayer or PBM drug policy; portal or phone
Prior authorization requirement and where to submitMedical-benefit and pharmacy-benefit drugs can route to different reviewersPayer or PBM policy; portal or phone
Step therapy, preferred product or formulary statusThe plan may require a different drug firstFormulary, payer drug policy; portal or phone
Site-of-care requirementsThe plan may review whether hospital outpatient infusion is medically necessaryPayer site-of-care policy; portal or phone
Sourcing: specialty pharmacy or buy-and-billDecides whether the practice may purchase and bill the drugPayer sourcing policy; portal or phone
Deductible, copay or coinsurance, out-of-pocket maximum, with amounts metSets what the patient owes on the drug and the administration271 or pharmacy response when populated; portal or phone
Codes the answer applies to (HCPCS or J-code, NDC)An answer for one code or formulation may not hold for anotherPayer policy and code lists; confirmed on the call or portal
Reference number, representative name, date and sourceLets your team trace and, if needed, dispute the answerPayer call or portal record

Prior authorization, step therapy and preferred products

HealthCare.gov defines preauthorization as a plan's decision that a service, treatment plan, prescription drug or equipment is medically necessary, and adds that it "isn't a promise your health insurance or plan will cover the cost." A BI records whether authorization applies and where it goes, because the reviewer can differ between the medical and pharmacy benefit. The BI does not replace the authorization; it tells the authorization team where to send it.

Medicare's drug plan rules page describes step therapy as "a type of prior authorization that requires you first to try a certain, less expensive drug on the plan's drug list" before moving up to a more expensive one. Commercial plans have their own versions: UnitedHealthcare's medical benefit specialty drug programs say that for certain specialty medications it "requires providers to use a lower-cost specialty medication before coverage for a clinically similar, higher-cost medication," and may require "lower-cost, self-administered medications available through the pharmacy benefit before we'll cover infused or provider-administered medications." So a BI on a medical-benefit infusion can still turn on pharmacy-benefit history.

Site of care and sourcing

Site-of-care rules decide where the plan will pay for an infusion. UnitedHealthcare's commercial Provider Administered Drugs, Site of Care policy (policy 2026D0121X, effective October 1, 2026) applies to drugs on its applicable medications list and sets criteria for hospital outpatient infusion. It names "non-hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion services" as alternative sites, which may be used when the patient does not meet the hospital outpatient criteria.

Sourcing decides who acquires the drug. UnitedHealthcare describes medication sourcing as an infusion provider receiving "a specialty medication from an outside specialty pharmacy," and says that if a medication has no sourcing requirement, "providers can buy-and-bill." In buy-and-bill, the physician purchases the drug, administers it and claims for both. "Covered under medical" without the sourcing answer leaves the most expensive question open.

Cost share and accumulators

The cost-share fields follow standard definitions. HealthCare.gov defines the deductible as "the amount you pay for covered health care services before your insurance plan starts to pay," a copayment as a fixed amount paid for a covered service, and the out-of-pocket maximum as "the most you have to pay for covered services in a plan year." The limit excludes premiums, non-covered services and out-of-network care, so amounts met matter as much as plan values.

The codes the answer applies to

CMS describes HCPCS Level II as a coding system "used primarily to identify products, supplies, and services" not included in CPT codes, and the J-codes for drugs belong to it. A BI should name the code it applies to, because payer rules attach to codes and products. New products show why: UnitedHealthcare's August 2026 specialty medication bulletin lists two medications added to review at launch, both under the codes J3490, J3590 and C9399 rather than a product-specific code.

NDCs matter too, especially for Medicaid. Under 42 CFR 447.520, a state must require providers to submit claims for certain physician-administered drugs "using National Drug Code (NDC) numbers," so a BI for a Medicaid patient should capture the NDC as well as the HCPCS code.

When to run a benefits investigation, and when to run it again

Run the BI before the first dose and before the drug is ordered. Once a practice has bought an expensive vial, learning that the plan required specialty pharmacy sourcing turns a coverage question into a reimbursement problem. The BI should also feed the authorization request so it reaches the right reviewer the first time.

A BI then goes stale for three reasons. First, plan years reset: HealthCare.gov defines a plan year as a 12-month period of benefits coverage under a group health plan that "may not be the same as the calendar year," so deductibles and out-of-pocket amounts can restart in the middle of a course of therapy. Second, eligibility changes when a patient changes jobs or plans, and authorizations can end with it. For the program changes it lists, UnitedHealthcare's August 2026 bulletin says it will honor approved prior authorizations "until the earlier of the end date on the authorization/notification or the date the member's eligibility changes."

Third, payer drug policies change on their own schedule. The same bulletin says that upon renewal "the updated policy will apply" and that providers "are encouraged to confirm whether prior authorization or other program requirements apply." For ongoing therapy, re-verify at the new plan year, when the patient reports new coverage, before an authorization renewal and when a policy update touches the drug.

Who performs benefits investigations

Benefits investigations for specialty therapies come from four broad service models. They differ mainly in who sponsors the work, which sources they use and what form the answer takes.

ModelHow it gets answersWhat it typically returns
Manufacturer hub programsReferral to the manufacturer's hub, which contacts payers about that productA coverage summary for the manufacturer's drug
Specialty pharmaciesPharmacy-benefit eligibility, PBM and payer contact for drugs the pharmacy dispensesCoverage and cost share for the dispensed drug
In-house practice staffEligibility tools, payer portals, policy lookups and payer callsNotes or a BI form in the practice management system or EHR
Automated or AI agent workflowsElectronic transactions, portals, APIs and payer phone lines, depending on the setupStructured fields with supporting records

Manufacturer hubs often run BIs for their own products. In OIG Advisory Opinion 18-14 (2018), a physician would "submit a referral to the Drug's reimbursement hub," and "the reimbursement hub would complete a benefits investigation." Some hubs also run patient support programs, which sit outside the BI itself.

Specialty pharmacies come into the picture when the drug is dispensed rather than bought and billed, including under medical-benefit sourcing rules like UnitedHealthcare's. In-house teams and automated workflows tend to handle the full mix of drugs a practice administers. The practical exercise is deciding, field by field, where each answer comes from for each payer.

How SuperDial handles benefits investigation work

For pharma patient access teams, SuperDial handles benefits verification, prior authorization, and payer and PBM follow-up, among other workflows. It uses AI across digital and voice channels to retrieve missing information, complete follow-up and return structured answers your team can act on. SuperDial can retrieve information from clearinghouses, payer portals, APIs and EDI where those sources are available, and when additional information is still needed, the workflow can continue by phone.

Teams can begin with batch uploads from an existing work queue and expand into APIs, webhooks and production integrations as the workflow matures. Each completed workflow returns the fields the workflow requires, along with a concise summary, next action, timestamps and supporting workflow evidence, and for voice interactions teams can review call recordings and transcripts. The benefits verification workflow returns coverage, cost-share and requirements fields in the same structured format.

When a payer cannot give a complete answer, the request comes back to your team as an exception with a summary of what happened and the recommended next action. SuperDial states that it is HIPAA compliant, SOC 2 Type II attested and HITRUST e1 certified, and a BAA is standard before any PHI is exchanged.

Interested in evaluating SuperDial?

SuperDial lists specialty benefits verification and payer and PBM coverage workflows among its suggested pilot starting points. A practical test is a real queue of upcoming therapy starts: bring the batch, define the BI fields you need back, and review the results. Book a demo to set one up.

FAQ

Is a benefits investigation the same as benefits verification?

The terms overlap, and usage varies. Here, "benefits investigation" means the drug-specific version: benefit type, authorization, sourcing and site of care for one therapy, on top of routine coverage and cost-share fields. Whatever you call it, define the field list so every request returns the same answers.

What information is needed to start a benefits investigation?

Start with patient demographics and member ID, the payer and plan, the prescribing and administering provider with NPI and tax ID, the drug's HCPCS code and NDC, the diagnosis, the planned site of care and the start date. A missing item can send the payer to the wrong policy or benefit.

Does a benefits investigation guarantee payment?

No. HealthCare.gov notes that preauthorization "isn't a promise" of coverage, and UnitedHealthcare's site-of-care policy says its documentation requirements "do not guarantee coverage of the service requested," with coverage determined by the member's benefit plan document and applicable laws. The reference number and source record let your team trace the answer if the claim is later denied.

Can Medicare Advantage plans use step therapy for infused drugs?

Yes, within limits. Under 42 CFR 422.136, an MA plan that uses step therapy for Part B drugs must apply step therapy "only to new administrations of Part B drugs, using at least a 365 day lookback period," with the program approved by its pharmacy and therapeutics committee. For a new MA patient on a Part B drug, record any step therapy requirement and prior use of the drug.

Sources

Run a pilot on a real workflow.

Bring a representative batch, define the output schema, and validate ROI with your payer mix in 30 to 90 days.